IDEXX LABORATORIES INC /DE 8-K

What Happened
IDEXX Laboratories, Inc. announced that Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, will cease her current role effective April 13, 2026 (Separation Date) and will provide advisory services as requested through July 13, 2026 (Final Employment Date). The company and Dr. Hunt entered a Separation Agreement on March 24, 2026, that sets out separation payments, advisory compensation and other terms.

Key Details

• Separation and advisory dates: Separation Date April 13, 2026; Final Employment Date July 13, 2026.
• Cash and benefits (aggregate potential amounts):
  • Salary continuation for 104 weeks: $1,230,000.
  • Target annual bonus for two years: $984,000.
  • Lump-sum COBRA premium payment: $50,000.
  • Transition assistance: $10,000.
  • Tax preparation/financial planning reimbursement up to $6,000 per tax year for 2025 and 2026 (up to $12,000).
  • Total potential cash/benefit outlay disclosed: $2,286,000 (plus per-diem advisor pay for days worked after Separation Date).
• Equity treatment: vesting of stock options, restricted stock units and performance stock units will cease as of the Final Employment Date; all unvested awards will be forfeited. Vested, exercisable options remain exercisable per existing award terms.
• Other terms: IDEXX states the position is being eliminated and treats the separation as a termination without cause for benefit purposes. The Separation Agreement includes a general release, non-disparagement and continuing cooperation obligations and reaffirms existing restrictive covenants.

Why It Matters
This 8-K reports an executive-level departure with a defined cash and benefits cost to IDEXX (about $2.29 million disclosed, plus any per‑diem advisory payments), and it eliminates future equity vesting for Dr. Hunt. For investors, the filing clarifies the company’s near-term cash impact, the treatment of executive equity, and that the separation was categorized as a termination without cause (which determined the benefit package). The agreement’s release and restrictive covenants reduce the risk of ongoing claims or competitive activity tied to this departure.